Celularity Inc. Stock News

Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist

Celularity is developing off-the-shelf placenta-derived allogeneic cellular therapies that overcome the problem of donor-patient match. The company was spun out from Celgene in 2016-2017.

FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic the

Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had pa

Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part

SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nas

Celularity announced it closed a merger with GX Acquisition Corp (NASDAQ: GXGX) and provided a corporate update. These are the details.

Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials. The combined company w